Paratek Pharmaceuticals, Inc.

202 articles with Paratek Pharmaceuticals, Inc.

• Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million

  8/3/2022

  Paratek Pharmaceuticals, Inc., reported financial results and provided an update on corporate activities for the quarter ended June 30, 2022.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Aug 01, 2022

  8/1/2022

  Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on July 29, 2022, the Company granted stock options to fourteen new employees of the Company.

• Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

  7/25/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the second quarter of 2022.

• Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)

  6/21/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced the U.S. Food and Drug Administration has granted Fast Track designation for the oral and IV formulations of the company’s novel, broad-spectrum antibiotic NUZYRA®.

• Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference

  6/1/2022

  Paratek Pharmaceuticals, Inc. announced that Evan Loh, M.D., chief executive officer, will participate in a fireside chat June 9 from 3:30 to 3:55 p.m. Eastern Time at the Jefferies Healthcare Conference in New York City.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 01, 2022

  6/1/2022

  Paratek Pharmaceuticals, Inc. announced that on May 31, 2022, the Company granted stock options and restricted stock units to twelve new employees of the Company.

• Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

  5/16/2022

  Paratek Pharmaceuticals, Inc. announced that Evan Loh, M.D., chief executive officer, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference.

• Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million

  5/4/2022

  Paratek Pharmaceuticals, Inc. reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 02, 2022

  5/2/2022

  Paratek Pharmaceuticals, Inc. announced that on April 29, 2022, the Company granted stock options to one new employee of the Company.

• Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

  4/26/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Apr 01, 2022

  4/1/2022

  Paratek Pharmaceuticals, Inc. announced that on March 31, 2022, the Company granted stock options and restricted stock units to ten new employees of the Company.

• Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million

  3/14/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021.

• Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA® (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium complex

  3/8/2022

  Paratek Pharmaceuticals, Inc. announced the publication of data from an investigator-initiated study evaluating the activity of NUZYRA® in a dynamic hollow fiber model of Mycobacterium avium complex pulmonary infection.

• Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

  3/2/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2021.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Mar 01, 2022

  3/1/2022

  Paratek Pharmaceuticals, Inc. announced that on February 28, 2022, the Company granted stock options and restricted stock units to six new employees of the Company.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Feb 01, 2022

  2/1/2022

  Paratek Pharmaceuticals, Inc. announced that on January 31, 2022, the Company granted stock options to six new employees of the Company.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Jan 03, 2022

  1/3/2022

  Paratek Pharmaceuticals announced that on December 31, 2021, the Company granted stock options and restricted stock units to two new employees of the Company.

• China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections Paratek earns $6 million milestone payment from Zai Lab

  12/16/2021

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of NUZYRA® (omadacycline) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 01, 2021

  12/1/2021

  Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on November 30, 2021, the Company granted stock options to ten new employees of the Company.

• Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference

  11/10/2021

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The on-demand presentation will be available Thursday, Nov. 18 beginning at 3 a.m. EST through Friday, Nov. 19 at 12 p.m. EST.